Eli Lilly is sharpening its competitive edge in the crowded oral SERD arena as the FDA has approved a combination of its ...

Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports.

Much like GSK (formerly GlaxoSmithKline) and the once Sanofi-Aventis (now just Sanofi), Novo Nordisk is slimming down its ...

Consumer drug behemoth Reckitt is dropping $600 million on a multi-year revamp of its U.S. operations. The health and hygiene ...

Novo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to ...

In their lawsuit, BMS and Ono accuse Amgen of aiming to market its biosimilar ahead of the expiration of key U.S. patents ...

In a push to free itself up for more R&D, Sanofi is acquiring a stake in German drugmaker, Cheplapharm. | In a deal that ...

Roche’s T-cell engager portfolio has notched another milestone, as a phase 3 trial of the company’s Lunsumio met its primary ...

Eli Lilly is marking World Alzheimer’s Day with a partnership to distribute 13,500 boxes of brain-healthy fresh produce and ...

Major drugmakers and top agencies alike earned their flowers at the annual Fierce Pharma Marketing Awards gala in ...

Following the news that longtime helmsman Paul Chaplin would be hanging up his hat at Bavarian Nordic earlier this year, the ...

Fayuvi, previously known as UX111, uses an adeno-associated viral vector to deliver a working copy of the SGSH gene into the patient’s cells. It marks the first FDA-approved therapy designed to ...